Financial Performance - Ekso Bionics reported a quarterly loss of $0.54 per share, better than the Zacks Consensus Estimate of a loss of $0.99, and an improvement from a loss of $1.5 per share a year ago, representing an earnings surprise of +45.45% [1] - The company posted revenues of $4.23 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.11%, compared to year-ago revenues of $4.13 million [2] - The current consensus EPS estimate for the upcoming quarter is -$0.54 on revenues of $5.65 million, and for the current fiscal year, it is -$1.17 on revenues of $15 million [7] Stock Performance - Ekso Bionics shares have declined approximately 46.2% since the beginning of the year, contrasting with the S&P 500's gain of 16.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Instruments industry, to which Ekso Bionics belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Ekso Bionics reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, and an improvement from a loss of $0.20 per share a year ago, indicating a negative earnings surprise of -9.09% [1] - The company posted revenues of $3.38 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.95%, and down from $3.76 million in the same quarter last year [2] - Over the last four quarters, Ekso Bionics has not surpassed consensus EPS or revenue estimates [2] Stock Outlook - Ekso Bionics shares have declined approximately 20.8% since the beginning of the year, compared to a decline of -3.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $6.32 million, and for the current fiscal year, it is -$0.25 on revenues of $23.99 million [7] - The estimate revisions trend for Ekso Bionics is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Ekso Bionics belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]